Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson's (NYSE: JNJ) TALVEY® (talquetamab-tgvs) demonstrated durable, long-term responses in patients with relapsed or refractory multiple myeloma (RRMM) in the Phase 1/2 MonumenTAL-1 study.
The study revealed a 24-month overall survival rate of 67% with biweekly dosing. Patients continued to show high response rates regardless of prior T-cell therapy exposure. At 23.4 months median follow-up, the median duration of response (DOR) was 17.5 months for biweekly dosed patients and 9.5 months for weekly dosed patients, increasing to 28.6 months in those with complete response or better. TALVEY® also exhibited low infection rates and manageable safety profiles.
The Phase 1b MonumenTAL-2 study with TALVEY® and pomalidomide showed an 88.6% overall response rate at a median follow-up of 16.8 months. The progression-free survival (PFS) rate at 12 months was 72.6%.
TALVEY® received FDA approval in August 2023 for treating RRMM in patients with at least four prior therapies.
A group of ovarian cancer victims has filed a motion in federal court to prevent Johnson & Johnson (NYSE: JNJ) from pursuing a third bankruptcy filing outside New Jersey. The company aims to resolve talc claims through a prepackaged bankruptcy plan in Texas, but the plaintiffs see this as a delay tactic to limit compensation. Past bankruptcy attempts by J&J in New Jersey were denied. The motion also seeks to prevent J&J from amending agreements without notifying the plaintiffs. The case, Rebecca Love, et al. v LLT Management et al., is filed in the U.S. District Court for the District of New Jersey.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call on July 17th at 8:30 a.m. Eastern Time to discuss its second-quarter results. The call will be led by CEO Joaquin Duato, CFO Joseph J. Wolk, and VP of Investor Relations Jessica Moore, with other executive team members participating in the Q&A session. The webcast and presentation materials will be accessible on J&J's investor website, with a replay available three hours post-conference. U.S. participants can dial in at 877-869-3847, while international participants can use 201-689-8261. The replay will be available until August 14th, using the ID 13746915.
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Shockwave Medical, integrating it as a business unit within Johnson & Johnson MedTech. This strategic move aims to enhance Johnson & Johnson's position in the cardiovascular intervention sector. Shockwave Medical is renowned for its intravascular lithotripsy (IVL) platform, used to treat coronary and peripheral artery diseases. The acquisition is projected to support revenue growth and strengthen Johnson & Johnson MedTech’s market leadership. However, the transaction will likely dilute adjusted earnings per share by $0.10 in 2024 and $0.17 in 2025 due to financing costs. Shockwave's common stock has ceased trading on NASDAQ.
Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire Numab Therapeutics' subsidiary for global rights to NM26, a Phase 2-ready bispecific antibody.
This $1.25 billion all-cash deal focuses on NM26, which targets IL-4Rα and IL-31 pathways in atopic dermatitis (AD). NM26 aims to address unmet needs in AD by offering a unique treatment for inflammation and itch.
The transaction is expected to close in the second half of 2024, pending regulatory clearance. Johnson & Johnson plans to develop more bispecific antibodies for AD and other immune-mediated diseases.
Johnson & Johnson (JNJ) has announced its acquisition of Proteologix, a biotechnology firm specializing in bispecific antibodies for immune-mediated diseases, for $850 million in cash, with additional milestone payments possible. Proteologix's pipeline includes PX128, entering Phase 1 trials for moderate to severe atopic dermatitis (AD) and asthma, and PX130, in preclinical development for AD. These therapies target IL-13, TSLP, and IL-22 pathways, aiming to deliver superior efficacy and patient convenience.
The acquisition aligns with JNJ's strategy to enhance its dermatology portfolio and address significant unmet needs in AD treatment. Proteologix's assets offer potential best-in-disease efficacy by targeting multiple disease pathways, addressing heterogeneous disease-driving factors in diverse patient populations.
Kenvue (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of common stock at $20.00 per share, expected to close on May 17, 2024.
Kenvue will not sell any shares or receive proceeds from the offering. Instead, Johnson & Johnson (NYSE: JNJ) is expected to exchange these shares for its indebtedness held by Goldman Sachs & Co. and J.P. Morgan, who will then sell the shares to underwriters.
Post-offering, Johnson & Johnson will no longer own any shares of Kenvue. The offering will be managed by Goldman Sachs, J.P. Morgan, BofA Securities, and others. A registration statement on Form S-1 has been filed and declared effective by the SEC.
Kenvue Inc. (NYSE: KVUE) has announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. The offering involves the exchange of shares between Kenvue and Johnson & Johnson, with Goldman Sachs & Co. and J.P. Morgan acting as selling shareholders. Following the exchange, the selling shareholders will sell the shares to underwriters. Johnson & Johnson will no longer own any shares of Kenvue's common stock after the completion of the offering.
Johnson & Johnson (JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, with key executives Jennifer Taubert and John Reed representing the company. The event will take place on June 12th at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors and interested parties can access the live webcast on the company's website. The audio webcast replay will be available after 48 hours.
Johnson & Johnson announced a Plan of Reorganization by its subsidiary, LLT Management , to resolve 99.75% of talc claims related to ovarian cancer through a consensual approach. The Plan commits to paying $6.475 billion to claimants over 25 years, far better than trial recovery. The Company stands by the safety of its talc products amidst meritless litigation.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
